Together, our findings show loss of Cntnap4 causes pro‐inflammatory cognitive decline that is effectively prevented by supplementation with microglia‐specific inhibitors; thus validating the targeting of microglial function as a therapeutic intervention in neurocognitive disorders. This evidence concerns the gene CNTNAP4 and Mental deterioration.